Comparative evaluation of the therapeutic efficacy between human amniotic epithelial cells and human umbilical cord mesenchymal stem cells in premature ovarian insufficiency

Our findings demonstrate that both hAECs and hUC-MSCs are effective in restoring ovarian function and fertility in a chemotherapy-induced POI mouse model. However, these two cell types exhibit distinct therapeutic advantages attributable to their differential metabolic kinetics and paracrine profiles. Specifically, hAECs displayed prolonged in vivo retention rates compared to hUC-MSCs, consistent with their enhanced antioxidant capabilities. In terms of secretory function, hAECs demonstrated superior pro-angiogenic activity, while hUC-MSCs exhibited stronger immunomodulatory effects. These distinct properties provide critical insights for cell-type-specific selection in developing targeted therapies for ovarian dysfunction.